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Mouse modelA mouse model of the devastating human disease “spinal muscular atrophy” (SMA) was used to investigate
the severe muscle weakness and spasticity that precede the death of these animals near the end of the 2nd
postnatal week. Counts of motor units to the soleus muscle as well as of axons in the soleus muscle nerve
showed no loss of motor neurons. Similarly, neither immunostaining of neuromuscular junctions nor the
measurement of the tension generated by nerve stimulation gave evidence of any signiﬁcant impairment in
neuromuscular transmission, even when animals were maintained up to 5 days longer via a supplementary
diet. However, themuscles were clearly weaker, generating less than half their normal tension. Weakness in 3
muscles examined in the study appears due to a severe but uniform reduction in muscle ﬁber size. The size
reduction results from a failure of muscle ﬁbers to grow during early postnatal development and, in soleus, to
a reduction in number of ﬁbers generated. Neuromuscular development is severely delayed in these mutant
animals: expression of myosin heavy chain isoforms, the elimination of polyneuronal innervation, the
maturation in the shape of the AChR plaque, the arrival of SCs at the junctions and their coverage of the nerve
terminal, the development of junctional folds. Thus, if SMA in this particular mouse is a disease of motor
neurons, it can act in a manner that does not result in their death or disconnection from their targets but
nonetheless alters many aspects of neuromuscular development.e), wes@mail.utexas.edu
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Spinal muscular atrophy (SMA) is a genetic disease characterized
bymuscle weakness that varies in severity and age of onset (Crawford
and Pardo, 1996; Monani, 2005). It is widely believed to be caused by
defects in spinal motor neurons. Severe forms of SMA are fatal and
constitute the leading genetic cause of mortality in infants. The
genetics of this complex disease is now well understood. All human
patients with SMA carry mutations in or deletion of both copies of a
telomeric gene “survival of motor neuron 1” or “SMN1” that codes for a
protein “SMN” that, surprisingly, is present in all cells in the body and
is believed to be involved in RNA processing (Burghes and Beattie,
2009; Lefebvre et al., 1995). Loss of all SMN results in embryonic
lethality. However, due to gene duplication, humans possess another
centromeric gene, SMN2, that is identical to SMN1 save for a silent
mutation that results in inefﬁcient splicing leading to a truncated
protein (SMNΔ7). SMNΔ7 is unstable and unable to compensate for
the loss of SMN1 (Lorson and Androphy, 2000). Full length SMN isproduced at only ~10% of the level encoded by SMN1 (Lorson et al.,
1999). The severity and onset of the disease in humans depend on the
number of copies of SMN2 present (Parsons et al., 1998). Thus, human
patients have a reduction in, rather than a loss of, SMN. A central issue
has been which tissues are most susceptible to this reduction and lead
to muscle weakness.
To investigate the disease, mousemodels have been generated (for
review see Park et al., 2010a). Since mice possess only a single smn
gene, the loss of which is embryonic lethal, transgenes to mimic the
second locus present in humans have been introduced into the smn
null background. For example, introduction of copies of the human
SMN2 gene and a transgene derived from the cDNA of SMNΔ7 yields
mice (termed SMAΔ7 mice) that display gross motor defects, fail to
thrive, and die near P16 (postnatal day 16) (Le et al., 2005). Studies
have been conducted on these mice in attempt to characterize the
nature of the defects both physiologically and morphologically. The
results of these studies have been rather divided as to the motor
neuron selectivity of the phenotype (for example Kariya et al., 2008;
Ling et al., 2010) — is SMA a motor neuron disease in which SMN
deﬁciency causes death selectively of motor neurons, leading
subsequently to muscle atrophy? Attempts at tissue-speciﬁc rescue
of SMN expression in these (or similar mouse models) suggest motor
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in other tissues has not been ruled out (Azzouz et al., 2004; Gavrilina
et al., 2008). Here we report our attempts to characterize the SMNΔ7
mice. Our ﬁndings suggest that muscle weakness is associated with a
slowed neuromuscular development that occurs in all 3 muscles we
examined but is not associated with motor neuron death or loss of
effective innervation of muscle ﬁbers. These results suggest that
alterations in morphology and behavior of multiple cell types of the
neuromuscular system affect the progress of the disease and that
neuromuscular activity rather than motor innervation per se plays a
role in the disease phenotype.
Materials and methods
Animals
Animal care and experiments were conducted in accordance with
National Institutes of Health guidelines and were approved by the
University of Texas Institutional Animal Care and Use Committee. The
SMAΔ7 mice were acquired from Jackson Labs (stock number
005025) with the assistance of the Spinal Muscular Atrophy
Foundation. These mice, originally generated in the laboratory of
Arthur Burgess (Le et al., 2005) are homozygous for each of two
transgenes (SMN2 and SMNΔ7) that allow mice that are homozygous
null for mouse smn and would otherwise die embryonically to survive
to the end of the second postnatal week. To maintain this colony
required only identifying mice heterozygous for deletion of smn, mice
that are fully viable. This was done by PCR for the detection of wild
type and knockout smn alleles, using primers previously described
(Schrank et al., 1997). Mice afﬂicted with SMA (i.e. those homozygous
mutant for smn; smn −/−) were identiﬁed in the progeny of
heterozygous mating stock. These mice could be easily identiﬁed by
P5 based on deﬁcits in ambulatory and righting behavior as well as
their small size, as described previously (Le et al., 2005). This
identiﬁcation could be conﬁrmed by genotyping using PCR. Animals
examined in this study were euthanized by intraperitoneal injections
of Nembutal (200 mg/kg).
To facilitate ﬂuorescence imaging of terminal Schwann cells (tSC),
an S100-eGFP transgene that marks SCs by their cytoplasmic
expression of enhanced green ﬂuorescent protein (Kang et al., 2003;
Zuo et al., 2004) was introduced into the SMAΔ7 line by interbreed-
ing. The offspring were successively backcrossed to SMAΔ7 mice to
place the S100-eGFP transgene in the FVB background of the original
SMA line. Mice with the S100-eGFP transgene were identiﬁed visually
by GFP ﬂuorescence present in the lens of their eye or by PCR (Zuo et
al., 2004). Mice hemizygous for the deletion of the mouse smn gene
were identiﬁed by PCR as described above. Mice homozygous for the
two original transgenes in this line (SMN2 and SMNΔ7) were
identiﬁed by quantitative PCR using reagents designed by Mary Ann
Mann and performed commercially (Charles River). Once mice
homozygous for these later two transgenes were identiﬁed, back-
crossing these mice to the original stock and simple visual and PCR
testing for smn and GFP were used to identify the animals of interest.
Backcrossing of SMAΔ7;S100-eGFP mice (Jackson Labs stock number
JR16573) has presently reached the 10th generation and no
substantial alteration in the survival time of the homozygous null
mice in the crossings has been noted.
Dietary supplementation of mutant SMAΔ7 mice
We tried in a few cases to extend the lifespan of the SMAΔ7 mice
by supplementing their diet. For this purpose, animals were fed up to
10 times a day beginning at P2–8, with small quantities of an artiﬁcial
diet formulated to simulate the protein content of rodent milk (one
part of puppy milk replacement [1.7 g Esbilac in 10 ml H2O] to four
parts human milk replacement [2 g Enfamil in 5 ml H2O] to a ﬁnalconcentration of 6.0 g of protein per 100 ml) (Barlow et al., 1974).
This liquid diet was fed from a syringe attached to a small cannula
pulled from polyethylene tubing by placing drops on the tongue and
allowing the animals to swallow the drop. Such treatment led to
weight gain and survival of animals. However, because the supple-
mentation did not alleviate the spasticity of the animals or their
failure to thrive, all these experiments were terminated before P21.
Tissue preparation and analysis
For electron microscopy (EM) of NMJs and morphometric analysis
of nerves and muscle ﬁbers, animals were perfused through the heart
ﬁrst with 0.1 M Sørensen's buffer (19 ml 0.2 M NaH2PO4, 81 ml 0.2 M
Na2HPO4, pH 7.4) followed immediately by EM ﬁx (2% paraformal-
dehyde and 3% glutaraldehyde in 0.1 M Sørensen's buffer). The
sternomastoid, extensor digitorum longus (EDL) and soleus muscles
were then exposed and ﬁxed in situ for 30 min. Muscles were then
dissected along with the associated nerve and ﬁxed overnight in the
same EM ﬁx, then washed in three changes of Sorenson's buffer,
10 min each. The tissues were then stained en bloc with 2% potassium
ferrocyanide and 2% osmium tetroxide for 2 h, washed with distilled
H2O, stainedwith 2% uranyl acetate for 2 h, washedwith distilled H2O,
dehydrated in increasing concentrations of ethanol that was then
changed to absolute acetone, and embedded in Epon 812 (Electron
Microscopy Sciences, Hatﬁeld, PA). Prior to embedding, muscle nerves
were removed from associated muscle by cutting proximal to any
branches at the site of muscle entry, embedded separately in Epon and
oriented so that the distal ends of the nerves were sectioned ﬁrst.
For counting muscle ﬁbers, semi-thick cross-sections (~500 nm)
were cut using glass knives and stained with 1% toluidine blue.
Sections were made approximately midway between the muscle
tendons so that no section counted contained tendon; therefore all the
ﬁbers in the muscle were counted. Digital images were captured of
sections viewed under Normarski optics in a light microscope. For
counting axons in the muscle nerve to soleus, cross-sections (65 nm)
were made using a diamond knife and digital images captured with a
transmission electron microscope (TEM; Tecnai, Hillsboro, OR).
Montages of entire muscle and nerve cross-sections were made on a
Macintosh computer (Apple Computer, Cupertino, CA) using Photo-
shop software (Adobe Systems, San Jose, CA). Measurements of
muscle ﬁber size and counts, and axon counts and diameter as well as
thickness of myelin were carried out using IPLab/iVision software
(BioVision, Exton, PA) by manually tracing individual muscle ﬁbers,
axons and the myelin sheath.
For ﬂuorescent labeling of muscle wholemounts, the animals were
transcardially perfused with PBS, pH 7.4. The sternomastoid, EDL and
soleus muscles were dissected and ﬁxed in 4% phosphate-buffered
paraformaldehyde, pH 7.4 for 20 min at room temperature and rinsed
in three changes, 5 min. each, of PBS.
For muscle ﬁber type determination, the sternomastoid, EDL and
soleus muscles were dissected from animals transcardially perfused
with PBS, pH 7.4, and fresh-frozen in Tissue-Tech Optimal Cutting
Temperature (OCT) compound (Ted Pella Inc., Redding, CA) with
liquid nitrogen. The blocks of muscles were cut on a cryostat (Hacker
Instruments, Winnsboro, SC) to produce 12-μm, serial sections at an
angle perpendicular to the long axis of the muscle ﬁbers.
Physiology
Soleus muscles were dissected, as described previously (Thompson,
1983b), with their innervation intact to the spinal cord to include the
twoventral roots, L4and L5, that containmotor axons to themuscle, and
pinned to a Sylgard-coated dish and superfused with oxygenated
Ringer's solution containing 2 mM Ca++. Muscle tension recordings
weremade at optimal muscle length by attaching the distal tendon to a
sensitive strain gauge (A408; Cambridge Technology, Lexington, MA).
434 Y. Lee et al. / Developmental Biology 356 (2011) 432–444Stimuli (1 ms duration) were applied to nerves via a suction electrode
and a Grass S88 Stimulator; contractions were monitored using an
oscilloscope. Direct muscle stimulation was accomplished by passing
100 V pulses of 1–2 ms duration applied between two platinum
electrodes located on each side of the muscle belly. The number of
motor units in eachmuscle preparationwasdeterminedbycounting the
threshold increments in tension generated as stimuli of gradually
increasing strength were applied to the ﬁlaments teased from the
ventral roots (Thompson, 1983b). If a ﬁlament contained more than 3
motor units, it was further teased and the resulting ﬁlaments were
analyzed to provide for more accurate counts.
Fluorescence immunohistochemistry
Muscles for whole-mount labeling of NMJs were prepared
as described above and immunostained as described previously
(Hayworth et al., 2006; Kang et al., 2007; Zuo et al., 2004). To label
surface nicotinic acetylcholine receptor (AChR) at NMJs, ﬁxedmuscles
were incubated with α-bungarotoxin (α-BTX, a snake toxin which
binds speciﬁcally and with high afﬁnity to AChR) conjugated to
tetramethyl-rhodamine or Alexa647 (1:500; Invitrogen, Carlsbad, CA)
prior to permeabilization. The presynaptic nerve terminals were
labeled with a mixture of monoclonal antibodies (mAbs) to
neuroﬁlament and synaptic vesicles (2H3 and SV2, respectively;
Developmental Studies Hybridoma Bank, University of Iowa, Iowa
City, IA) and an anti-mouse antibody conjugated to FITC (Cappel,West
Chester, PA). To assay for neuroﬁlament accumulation in endplate
area, a rabbit anti-synaptophysin antibody (Invitrogen) and an anti-
rabbit antibody conjugated to TRITC (Cappel) were used to label
synaptic vesicles and with mAb 2H3. Synaptic basal lamina proteins,
acetylcholine esterase (AChE) and laminin β2, were labeled with
fasciculin2 (Sigma-Aldrich, St. Louis, MO) conjugated to cyanine5
(Cy5; Invitrogen), rabbit anti-laminin β2 antibody (Sasaki et al., 2002)
and an anti-rabbit antibody conjugated to TRITC (Cappel), respec-
tively. For counts of SCs, 4′,6-diamidino-2-phenylindole (DAPI; 0.5 μg/ml)
was used as a stain for nuclei. For ﬁber typing, serial muscle cross-
sections (see above) were stained with mouse monoclonal myosin
heavy-chain (MHC) speciﬁc antibodies (Developmental Studies
Hybridoma Bank) and anti-mouse antibodies conjugated to FITC
(Cappel). The mAbs to MHC used were: A4.840 (type I; slow), A4.74
(type IIa), 10eF5 (type IIb), 6H1 (type IIx), F1.652 (embryonic) and
A4.1025 (pan MHC). Muscle ﬁbers expressing a given MHC isoform
were represented as a percentage of total number of myoﬁbers in the
muscle. Images were acquired using a Leica (Nussloch, Germany)
DMR epiﬂuorescence microscope equipped with a Hamamatsu
cooled CCD camera controlled by a Macintosh computer with
IPLab/iVision software.
Ultrastructural examination and 3-dimensional reconstruction of NMJs
EDL muscles from P14 mutant SMAΔ7 mouse and control
littermates were processed for TEM as described above. Serial thin
sections (65 nm) were made through a single synapse in each muscle
using a diamond knife. Random sampling was also used to obtain
images of other NMJs. EM images of synapses were captured with a
digital camera and montages encompassing the synapse on one
muscle ﬁber were prepared using Photoshop. A serial series of
montaged TEM images from muscle serial sections were then used to
create a 3-dimensional rendering of the NMJ and its cellular
components using “Reconstruct” software (Fiala, 2005). Additionally,
the following synaptic components were traced/segmented for
quantitative comparison of mutant and control NMJs: secondary
synaptic folds in postsynaptic muscle membrane, nerve/muscle
contact, and synaptic vesicles. Vesicles were traced individually
when possible, however, those in close proximity to others weretraced as clusters when traces for individual vesicles would likely
overlap.
Quantiﬁcation of synaptic labeling
To differentially quantify the topology of postsynaptic AChR
aggregates, we categorized each junction into one of the 4 types:
simple plaque, perforated plaque, open or C-shaped and branched
(Kummer et al., 2004). The same synapses were also scored for the
junctional (or secondary) folds indicated by the presence of “stripes”
of α-BTX label (Marques et al., 2000) and placed in one of the
following 4 categories: no stripes (absent), short and disorganized
stripes (disorganized), stripes over more than ~25% (partial) and
~75% (full) of the AChR aggregate. Statistical analysis of raw data and
the generation of histogramswere performed using Excel spreadsheet
software (Microsoft, Redmond, WA). Numerical data are reported as
mean±SEM.
Results
Counts of motor units and axons suggest no signiﬁcant motor neuron
loss
The precise nature of the defects in the SMAΔ7 mice that
phenocopy a severe form of human SMA remains unknown. If the
disease were indeed produced by death of motor neurons, then
physiological and histological analyses would be expected to reveal
reductions in their number. Recognizing many of the difﬁculties of
obtaining accurate motor neuron counts by histology of the spinal
cord, we resorted to two alternative approaches: 1) counting axons in
images from transmission electron micrographs of muscle nerves and
2) counting motor units as the increments in muscle twitch tension.
We focused our efforts on SMA end-stage animals (i.e. those at P12–
14) since motor neuron death has been reported to be a late event in
SMAΔ7 disease progression (Le et al., 2005).
First, examination of the electron microscopic images from P13
soleus nerves of 3 mutants and 3 control littermates (Figs. 1A, A′)
showed no difference in the number of axons, either myelinated or
unmyelinated (Fig. 1B). In addition, there was no difference in the
degree of myelination of axons in the motor nerves as assessed by g-
ratio measurements (Fig. 1C). Our detailed analysis of axon number
and their state of myelination as a readout of their integrity in control
and mutant nerves conﬁrms the initial qualitative assessment of
SMAΔ7 mutant nerves by Sumner and colleagues (Kong et al., 2009),
and argues against the idea that motor neuron axons are dying back
from their target muscle ﬁbers (McGovern et al., 2008). While the
axon count suggests there is not an obvious loss of motor neurons, it
provides no information on the functional health of these motor
neurons. Therefore, to be certain that the number of healthy motor
neurons was indeed unaltered, we estimated the number of motor
units in soleus muscles from a set of mutants and their littermate
controls at P12–14 by counting increments in the twitch tension from
stimulating ﬁlaments teased from the ventral roots. Since this method
assays tension development from nerve stimulation, it determines
whether motor neurons make functional connections with muscle
ﬁbers. The numbers of units found in control muscles were 16, 15, 13
and 15 (4 muscles from 4 animals); those in mutant muscles were 14,
15, 13, 14 (4 muscles from 4 animals) (Fig. 2A). Thus, there appears to
be no signiﬁcant loss of motor neurons in soleus muscles even at the
end-stage of disease progression in SMAΔ7 mice.
The apparent lack of motor neuron death in mice is not consistent
with reports for the human disease. One possible explanation of the
inconsistency is that the mice die before motor neuron deﬁcits
become evident. Indeed, the mutant SMAΔ7 mice may cease to feed
from their mother and this may contribute to their death. We found
that these mutant mice could be maintained for a longer period by
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Fig. 1. No axon loss or change in myelination in nerve to the soleus muscle in SMAΔ7
mutant mice. EM cross-sections of soleus muscle nerves from P13 littermates, A. control
nerve. A′ mutant, SMA nerve. Sections were made proximal to the branch just outside
themuscle. Scale bar=10 μm. B, Numbers of axons (myelinated, unmyelinated, and the
total) found in 4 control and mutant soleus nerves were not statistically different. C, g-
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Fig. 2. Nerve evoked contractions show mutant muscles are weak but provide no
evidence of motor neuron death or deﬁcits in neuromuscular transmission. A, The
number of motor units counted in P12–14 control soleus muscles (14±0.63) did not
differ signiﬁcantly from those in mutant littermates (14.75±0.41, pN0.36), or P17
hand-fed mutant mice (15±1, pN0.84). B, Isometric contractions of P13 control and
mutant, SMAΔ7 soleus muscles to stimuli applied to the muscle nerve. A 1.5 s duration
train of stimuli was applied at frequencies of 5, 10, 20 and 60 Hz. Although the mutant
muscle generated less than half the tension of the control, each stimulus applied
generated a reliable muscle contraction. C, Response of control and mutant muscle to a
7.5 second duration tetanus at 60 Hz. Both muscles responded without obvious signs of
fatigue or transmission failure. Calibration: 1 g/100 ms for A; 1 g/1 s for B.
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experiments that were terminated at P17, P20 and P21. The
supplemented animals outlived other mutant animals and responded
with a modest but signiﬁcant increase in body weight. At P13
supplemented pups weighed 4.2±0.4 g compared to 3.0±0.1 g for
non-supplemented littermates (n≥6, pb0.01); at P19 supplemented
pups had continued to gain some weight, reaching 4.8±0.2 g (n=3).
The number of motor units counted in these mutant muscles was 13,
16 and 16, comparable to those counted in soleus muscles of mutant
or controls at P12–14 (Fig. 2A). Counts of axons and motor units,
together, provide the most deﬁnitive functional evidence to date that
disease pathology in SMAΔ7 mutant mice, at least in the soleus
muscle, is not due to death of motor neurons or dying back of their
axons from their muscular targets. These ﬁndings are also in
agreement with a report from Monani and colleagues where motor
neuron death is a relatively late event in SMAΔ7 disease progression
(Le et al., 2005) andwheremotor deﬁcits precedemotor neuron death
in a new SMA mouse model (Park et al., 2010b). Therefore, even at an
age beyond its normal lifespan, there appeared to be no apparent
deterioration in the number of functional motor units in the soleus
muscle of mutant SMAΔ7 mice.Mutant soleus muscle contractions are consistent with reduction in
muscle mass without gross defects in neuromuscular transmission
As our histological and physiological assays suggested no signiﬁcant
loss of motor neurons, we asked whether the motor deﬁcits of SMAΔ7
mice (Butchbach et al., 2007) could be attributed to failure of synaptic
transmission at the mutant neuromuscular junction. Soleus muscles,
together with their nerves, were dissected from the hindlimbs of
SMAΔ7 mutant mice and their unaffected littermates, and the tension
generated in response to suprathreshold stimulation of the muscle
nerve was measured. Consistent with the smaller size of the mice
themselves (Le et al., 2005), mutant soleus muscles were noticeably
smaller than their control counterparts at P13 (Fig. 3A). The
contractions of the muscles were measured in response to stimulus
frequencies giving fused and unfused tetani (Fig. 2B). While mutant
muscles always gave half or less the tension of control muscles, they
responded faithfully to each nerve stimulus with a contraction. This
high ﬁdelity of neuromuscular transmission was maintained in soleus
muscles isolated from mutant SMAΔ7 animals maintained past their
normal lifespan by means of supplemental diet (data not shown). In
addition, the mutant muscles maintained tension as competently as
littermate controls even when subjected to stimulation for 7.5 s at
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436 Y. Lee et al. / Developmental Biology 356 (2011) 432–444100 Hz to produce a fused tetanus (Fig. 2C). The ability of mutant
muscles to respond to each nerve stimulus and hold tension suggests
that neuromuscular function remains suprathreshold. Lastly, direct
stimulation of the muscle yielded the same twitch tension as did nerve
stimulation (data not shown), suggesting there is not an extensive
population of denervated ﬁbers in the mutant muscle. Therefore, the
weakness of SMNΔ7 soleus muscles is unlikely to result from loss of
innervation to individual muscle ﬁbers in soleus muscles. It appears
that cholinergic transmission at theNMJs remains intact and our results
are in good agreement with a recent report of effective transmission at
SMAΔ7 mutant NMJs (Ling et al., 2010). Thus, the muscle weakness in
mutant SMAΔ7 mice may be a consequence of the smaller size of the
muscles or some kind of inability to execute functional motor patterns
in the spinal cord.Impaired postnatal growth of SMAΔ7 mutant muscles
The reduction in muscle mass observed in SMAΔ7 mutant mice
could result from smaller and/or fewer individual muscle ﬁbers. Gross
examination of muscle cross-sections used for muscle ﬁber typing
suggested that the mutant muscle ﬁbers are signiﬁcantly smaller
(Fig. 3A). To explore this issue more thoroughly, we examined
muscles at P13. In attempt to prevent unintended alterations of
muscle ﬁber cross-sectional area during processing of the tissue, we
ﬁxed muscles in situ at resting muscle length. After post-ﬁxation and
embedding in epon, semi-thick (500 μm), plastic sections were
examined in the light microscope. Consistent with previous reports
(Kong et al., 2009; Le et al., 2005), the average cross-sectional area of
P13 mutant soleus muscles is signiﬁcantly reduced compared to that
437Y. Lee et al. / Developmental Biology 356 (2011) 432–444of control littermates (168±2 vs. 764±8 μm2; ***pb0.001, Student's
T-test) (Fig. 3B). More importantly and not previously noted, the
distribution of individual ﬁber areas (Figs. 3C, D) shows that mutant
ﬁbers are uniformly decreased in diameter. This suggests that there is
not a subpopulation of motor neurons dying and leaving denervated
ﬁbers. Rather, it appears that whatever is altering the size of the
muscles alters every ﬁber in the muscle. We also observed the same
uniform reduction in ﬁber size in two additional muscles examined,
the sternomastoid (mean: 311±2 vs. 746±4 μm2; ***pb0.001;
Fig. 4) and EDL (mean: 169±2 vs. 583±6 μm2; pb0.001; and data
not shown). Thus, the reduction of SMN expression appears to
produce a reduction of muscle ﬁber size in both a slow and fast twitch
muscle in the leg and a proximal and anterior fast muscle. Given the0 
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asterisks indicate statistical signiﬁcance of comparisons (***pb0.001).small size of the animals, it is likely this reduction occurs in many, if
not all, muscles throughout the animal.
To determine whether this reduction in muscle ﬁber size is due to
impaired muscle ﬁber growth or to atrophy, we compared muscles at
P13 with those present at an earlier time, P5. P5 control soleus muscle
ﬁbers are signiﬁcantly larger than those in the P5 mutants, although
the difference in size (Fig. 3B; 171±2 vs. 220±2 μm2; *** pb0.001) is
much less than at P13. Again, the distribution in sizes shows that the
size reduction at P5 is not in a subpopulation of ﬁbers (Figs. 3C, D).
While the control muscle ﬁbers undergo tremendous growth in size
the next 8 days (from 220±2 to 764±8 μm2), the mutantmuscles do
not grow (from 168±2 to 171±2 μm2). A similar result is obtained
for the sternomastoid muscle ﬁbers (Figs. 4B, C): a uniform reduction
in size is evident at P5 (206±2 vs. 262±2 μm2; ***pb0.001) and their
growth during the next 8 days is signiﬁcantly impaired compared to
controls (from 206±2 to 311±2 μm2 vs. from 262±2 to 746±
4 μm2). Thus our ﬁndings are consistent with those of Sumner and
colleagues (Kong et al., 2009) and argue that muscles of SMAΔ7
mutant mice do not undergo atrophy, but rather fail to grow in size
during their early postnatal development.
It is possible that this lack of postnatal muscle development is
strictly a consequence of the SMAΔ7 mutant mice to thrive. However,
in analyzing a soleus muscle from a hand fed P17 mutant mouse
(Fig. 3A), we found that the average ﬁber size (170±2 μm2) and
distribution of ﬁber sizes are unaltered when compared to those from
non-supplemented P13 mutant soleus muscles (Fig. 3D), further
suggesting that mutant muscle ﬁbers are not undergoing atrophy. In
contrast, SMAΔ7mutantmice that are supplementedwith an artiﬁcial
diet continued to grow and were signiﬁcantly bigger, at P17, than
non-supplemented P13 mutants (4.45 g±0.31 vs. 3.09 g±0.13;
n≥4; pb0.001). Therefore, the retarded growth of mutant muscle
and its ﬁbers can be decoupled from the animals' body weight and
inability to grow. Moreover, electron microscopic examination of
individual muscle ﬁbers from both control and mutant P13 soleus
muscles failed to reveal ultrastructural changes associated with
atrophy (Lu et al., 1997) such as disorganization of sarcomeric
structures and loose folds of basal lamina in and around mutant
muscle ﬁbers (Fig. S1).
Mutant soleus muscles, but not sternomastoid or EDL muscles,
displayed an additional difference from the same muscles in normal
siblings. At P13, mutant soleus muscles had 15% fewer ﬁbers than
those of control littermates (532±14 vs. 623±26 or 86±3% of
control; n=3, * pb0.05; Fig. 3E). There also appeared to be fewer
ﬁbers in mutant soleus muscles at P5 (490±7 vs. 552±64 or 90±
12% of control; n=3, pN0.469; Fig. 3E), although the difference did
not reach statistical signiﬁcance. The deﬁcit in ﬁber counts persisted
in soleus muscles of 2 animals fed with an artiﬁcial diet (387 and 497,
at P17 and P21 respectively, compared to 628 and 618 of age-matched
littermates). Although the small sample size limits statistical analysis,
there appeared to be a small reduction in the number of mutant soleus
ﬁbers after P13. Thus, the mutant muscle ﬁbers may become more
susceptible to damage and degeneration over time. A similar
reduction in the number of ﬁbers was found in a mutant EDL muscle
at P17 (1037 compared to 1353 for a control littermate). Any loss of
ﬁbers in the hindlimb muscles did not appear to be compensated for
by regeneration as the proportion of ﬁbers with centrally located
nuclei, a marker for regenerated ﬁbers, was comparable in mutant
muscles and controls (data not shown). Interestingly, skeletal muscle
progenitor cells, a subset of muscle satellite cells that are essential for
muscle growth and repair, have been reported to exit early from the
cell cycle and undergo premature differentiation in SMA muscles
(Bennett, M.H., Cerletti, M.,Wagner, A., Wagers, A., and Rubin, L.L.
2009 American Society for Cell Biology meeting abstract #428).
Therefore, the deﬁcit in muscle ﬁber number in soleus seen at the
terminal stage of disease may result from a reduced capacity for
muscle growth and repair of damaged ﬁbers.
438 Y. Lee et al. / Developmental Biology 356 (2011) 432–444Pattern of myosin heavy chain expression reveals lack of myoﬁber
maturation in SMAΔ7 mutant mice
Defects in postnatal generation and/or growth of muscle ﬁbers
suggested that SMAΔ7mutantmuscle ﬁbers might also be less mature
than those in the control muscles. Sumner and colleagues reported
alteration of mRNA levels of individual MHC isoforms in SMAΔ7
mutant hind leg muscles that is consistent with lack of postnatal
maturation (Kong et al., 2009) — increased perinatal isoform vs.
decreased adult isoforms. To directly test whether these defects
represent global changes across muscles at the protein level and
whether individual muscle ﬁbers continue to differentiate, cross-
sections of P12 control and mutant SMAΔ7 sternomastoid and soleus
muscles were labeled with isoform-speciﬁc anti-MHC monoclonal
antibodies (Condon et al., 1990a,b). Fibers labeling for slow myosin
were present in a scattered pattern in the deep portion of
sternomastoid muscles of both control and mutant animals
(Figs. 5B,B′). In soleus muscles, ﬁbers labeling for slow myosin were
more prevalent and were scattered throughout both control and
mutant muscles. Thus, slow ﬁbers appear in the expected locations in
these muscles and there is no evidence for clustering of these slow
ﬁbers into contiguous groups as might be expected if the ﬁbers had
undergone rounds of denervation and reinnervation by sprouts
(“ﬁber type grouping”). Interestingly, however, we found a muscle-
speciﬁc reduction in the abundance of muscle ﬁbers expressing fast
myosin in mutant muscles when these were compared to theirP1
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the proportion of muscle ﬁbers that expressed the embryonic isoform
of myosin heavy chain in sternomastoid muscles of the SMAΔ7
animals (Fig. 5C). Consistent with the normal slower development of
soleus compared with more anterior muscles (Condon et al., 1990a),
virtually all the ﬁbers in both control and mutant soleus expressed
embryonic MHC. These ﬁndings are also consistent with persistent
expression of embryonic MHC isoform in muscles from a different
SMA model (Biondi et al., 2008), and in human SMA patients
(Martinez-Hernandez et al., 2009; Stevens et al., 2008), but provide
additional information that the regional differentiation of ﬁber types
within muscles is maintained. Taken together, these ﬁndings suggest
that ﬁbers in mutant muscles, in addition to their smaller sizes, are
generally less mature than those in controls.
Muscle-speciﬁc impairment of neuromuscular synaptic morphology in
SMAΔ7 mutant mice
To determine whether there were alterations in themorphology of
NMJs in SMAΔ7 mice, we ﬂuorescently labeled motor axons,
presynaptic nerve terminals, and postsynaptic muscle membranes
with antibodies to neuroﬁlament and to synaptophysin, and with
ﬂuorochrome conjugated α-BTX, respectively (Fig. 6A). Pre- and
postsynaptic labels resemble each other in shape and occur in good
register. We failed to detect any obvious signs of denervation orEmbryonicow
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439Y. Lee et al. / Developmental Biology 356 (2011) 432–444terminal sprouts originating from intact NMJs in all 3 muscles
examined between P10 and 14 (data not shown; also see Kong et
al., 2009; Ling et al., 2010). However, a closer examination of mutant
NMJs and their cellular components revealed muscle-speciﬁc defects
in synaptic maturation. First, approximately 40% of the endplates in
SMAΔ7 mutant sternomastoid muscle were apparently polyneuron-
ally innervated based on the entry into the synaptic site of two or
more preterminal axons. In many cases these preterminal axons could
be followed for a distance ranging from 37 to 95 μm (70±4 μm;
n=13 polyneuronally innervated endplates) along the pathway
leading to the synaptic site, suggesting they are branches of different
rather than the same motor neurons. In contrast, no polyneuronally
innervated junctions were found among the control sternomastoid
NMJs examined (Fig. 6B). No difference in polyneuronal innervation of
control and mutant soleus muscles was found. Here, however, both
the mutant and control muscles had a signiﬁcant number of endplates
that appeared to be multiply innervated, and any difference in the
extent of polyneuronal innervation, if present, would be less obvious.
We interpret these ﬁndings as showing a delay in the loss of
polyneuronal innervation in an anterior muscle; this delay however
is not obvious in more posterior muscles where normally polyneur-
onal innervation is lost later in development.
Consistent with previous characterization of NMJs in SMA mouse
models (Cifuentes-Diaz et al., 2002; Kariya et al., 2008; Kong et al.,
2009; Murray et al., 2008), we found abnormal accumulations ofneuroﬁlaments at mutant synapses. However, as was the case with
delay in elimination of polyneuronal innervation, sternomastoid
muscles were more severely affected than soleus muscles (Fig. 6C):
97±1% and 76±6% (n=3; pb0.05) of NMJs in sternomastoid and
soleus, respectively, displayed neuroﬁlament accumulation. Interest-
ingly, the morphology of the neuroﬁlament accumulations also
differed between the two muscles (Fig. 6A). Virtually, all of the
neuroﬁlament accumulations in NMJs of sternomastoid appeared
“bulbous” and extended to the very tips of the nerve terminals
(asterisk in Fig. 6A; SMA, 94.4±0.7% vs. Control, 7.38±0.6%;
pb0.001). In contrast, more than half of soleus NMJs with neuroﬁla-
ment accumulation had a “frayed” or “webbed” appearance of the
presynaptic axons (§ in Fig. 6A; SMA, 54.14±6.67% vs. Control, 32.3±
4.95%; pb0.001). Explanations for the disorganization in neuroﬁla-
ments are presently lacking.
Postsynaptic AChR aggregates initially appear as simple plaques
and become successively more complex as “perforated” plaques,
“C”-shaped, branched conﬁgurations, and eventually mature “pretzels”
(Kummer et al., 2004). This progressive differentiation is severely
stunted in NMJs in mutant sternomastoid muscles (Fig. 7A) in
agreement with reports of postsynaptic morphology at mutant NMJs
(Kariya et al., 2008; Kong et al., 2009). In P12 control sternomastoid,
virtually all AChR aggregates have evolved past the plaque stage and
have obtained open-conﬁgurations (C-shaped or branched). In the
sternomastoid of mutant siblings, more than 40% of receptor
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440 Y. Lee et al. / Developmental Biology 356 (2011) 432–444aggregates are still plaque-shaped and only about 20% have reached
the open conﬁgurations, while the remaining 40% have undergone
partial transformation and are perforated. Interestingly, the defects in
AChR maturation are less evident in mutant soleus and EDL muscles
(Fig. 7B); however, even control junctions of these muscles are
immature at this stage of postnatal development, consistent with the
known anterior–posterior gradient in development of neuromuscular
synapses. Mutant NMJs are also defective in forming secondary
junctional folds (Figs. 7A,C; also see below), another indicator of
postsynaptic differentiation. Junctional folds, which appear as stripes of
BTX labeling in NMJs viewed en face in the confocal microscope
(Marques et al., 2000) are present in parts or all of the postsynaptic area
in more than 70% of NMJs in P12 control sternomastoid muscles. In
contrast, a large majority of NMJs in sternomastoid muscles of mutant
littermates show patchy, short and/or disoriented stripes of AChR
aggregates (Fig. 7B). Differences between the pattern of striping in
control and mutant junctions of soleus and EDL muscles are far less
obvious (Fig. 7B); even control junctions appear relatively immature in
this feature. Thus, just as the case for polyneuronal innervation
presented above, the differences in control and mutant junctions are
present in those muscles more advanced in development and less
obvious in those that are immature.
The vertebrate NMJ is a tripartite synapse. In addition to the
presynaptic motor nerve terminal and the postsynaptic muscle
membrane, terminal Schwann cells (tSCs) at the NMJs are criticalfor structural integrity and growth of the synaptic contact (Reddy
et al., 2003). To examine the number and distribution of non-
myelinating tSCs at the junction we introduced into the SMAΔ7
mutant mice a transgene coding for expression of soluble GFP by
interbreeding with the previously described Kosmos transgenic
line (Zuo et al., 2004). The number of tSCs is signiﬁcantly reduced
in mutant mice (Figs. 8A–C). This deﬁcit was evident in both
sternomastoid (2.1±0.1 vs. 4.9±0.1 per mutant and control NMJ,
respectively; n≥149 junctions from 2 control and SMA animals,
*** pb0.001) and soleus muscles (2.4±0.08 vs. 3.6±0.1 per mutant
and control NMJ, respectively; n≥143 junctions from 2 control and
SMA animals, *** pb0.001). This reduction in number is correlated
with reduced endplate area (Fig. 8D)which, in turn, is likely due to the
smaller muscle ﬁbers (Love and Thompson, 1998). In addition, we
found the coverage of postsynaptic AChR aggregates by the terminal
SCs to be incomplete at some mutant NMJs in contrast to control
synapses (example in Fig. 8B; see also Fig. 9C′). As the cell bodies of
SCs normally arrive at the NMJ after the synapse has been formed
(Love and Thompson, 1998), the reduced number and incomplete
coverage suggest abnormal or delayed development of SMAΔ7 NMJs.
Given that tSCs in turn play an important role in the growth and
physiology of developing NMJs (Reddy et al., 2003), SMA junctions are
deﬁcient here as well.
As a recent report has provided evidence of wide-spread splicing
defects in SMAΔ7 mice and suggested that long transcripts –many of
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Fig. 9. Ultrastructure of neuromuscular junctions shows structural changes in mutant
junctions. EMs of control (A) and mutant (A′) P14 EDL NMJs. The three cellular
components are indicated: m, postsynaptic muscle ﬁber, nt, presynaptic motor nerve
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as the caveolae-like structures (arrowheads). 3D reconstructions were rendered from
serial EMs of control (B,C) and mutant (B′,C′). NMJs in the EDL muscle. The 3D
reconstructions of the nerve terminal in B and B′ were rotated so as to view the NMJs
from the top. The mutant nerve terminal (in blue) is less complex. The reconstructions
in C and C′ show the junctions viewed from inside the muscle ﬁbers. The junctional
folds, in red, are almost completely lacking in the mutant. The tSC (in green)
incompletely covered the nerve terminal and its processes in the mutant (double
arrowhead in C′). Scale bars in A–A′=500 nm and B–C′=2 μm.
441Y. Lee et al. / Developmental Biology 356 (2011) 432–444which yield extracellular matrix proteins – are more susceptible to
aberrant splicing in mutant mice (Zhang et al., 2008), we tested
whether there were alterations in the localization of components of
the synaptic basal lamina. We examined the localization of the
enzyme acetylcholine esterase and of laminin β2 (s-laminin), which
has recently been demonstrated to organize active zones of motor
axon terminals (Nishimune et al., 2004). These were seen to co-
localize with the postsynaptic AChR at both control and mutant NMJs
(Fig. S2); thus there is no obvious deﬁciency in synaptic distribution of
these molecules.
Ultrastructural examination of mutant SMAΔ7 NMJs
In an attempt to better understand the structural changes that
occur at the synapses in the mutant muscles, we examined several
control and mutant NMJs between P10 and 14 in the electron
microscope. A sampling of NMJs encountered in random sections in
these muscles suggested that there were several alterations (Figs. 9A,
A′): postsynaptically, there were fewer and shallower secondary
junctional folds; presynaptically, nerve terminals had fewer and more
scattered synaptic vesicles.
To extend and quantify these preliminary observations on the
ultrastructural changes in SMAmuscles, we prepared three-dimensional
(3D) renderings of serial electron micrographs of NMJs from a
control and amutant P14 SMAΔ7 EDL muscle. A set of approximately
100 serial, ultrathin (65 nm) sections, representing coverage of
approximately 6.5 μm along the long axis of the muscle ﬁber, was
collected. Digital images were prepared of the junction in each section
and these sections aligned in software. Each structure of interest – the
nerve terminal, the SCs, synaptic vesicles, and the junctional folds in
the muscle membrane – was segmented in software. Three-D
projections of these images were prepared and segmented objects
quantiﬁed. Presynaptically, the 3D rendering of control and mutant
nerve terminal viewed from above (Figs. 9B,B′) showed that the
mutant nerve terminal is smaller and less branched. In fact, in contrast
to the control junction, there were no interruptions in the cytoplasm
of this mutant nerve terminal where it was in close contact with the
muscle ﬁber membrane. These features are consistent with the
simpliﬁed morphology of nerve and AChR in the mutant junctions
442 Y. Lee et al. / Developmental Biology 356 (2011) 432–444seen in the light microscopy (Figs. 7A,B). Additional defects were found
upon closer examination. There was a reduction in the number of
synaptic vesicles in the mutant nerve terminal: vesicles in the
mutant nerve terminal occupied a volume of 5.43 μm3 compared to
12.01 μm3 in controls. Even after correcting for the smaller size of
their nerve terminals, the mutant had roughly 1/3 fewer vesicles
(21.7% of the volume in the mutant terminal vs. 33.7% in the control),
consistent with recent reports of reduced vesicle pool and quantal size
of SMAΔ7 mutant motor nerve terminals (Kong et al., 2009; Ling et al.,
2010; Ruiz et al., 2010). In addition, despite occupying a smaller
portion of the nerve terminal the vesicles were more dispersed in the
mutant: there were more vesicle clusters (8311 vs. 4437) and these
clusters were smaller in size. The most profound and obvious change
was found postsynaptically. Secondary junctional folds were reduced in
the muscle ﬁber membrane in the SMAΔ7 mice (Figs. 9C,C′); the
volume of the secondary folds was about 14 fold greater in controls
after normalizing for the area of synaptic contact (0.081 vs.
0.006 μm3/μm2). This reduction is consistent with the inferences
from our light microscopic observations (Figs. 7A,C) and, since such
folds are added gradually during early postnatal development
(Marques et al., 2000), consistent with a developmental delay in the
SMA muscles. While cellular and molecular mechanism(s) responsible
for formation of junctional folds are unclear, the deﬁcit in the SMA
muscles may be related to a marked reduction in the number and
frequency of vesicles associated with postsynaptic membrane
(Figs. 9A,A′ inset). These vesicles appear to have fused with the
plasma membrane in some instances and have ﬂask-shape proﬁles
reminiscent of caveolae (Woodman et al., 2004). We ﬁnd less than 1/2
the number of these postsynaptic vesicles per unit length of synaptic
contact at the mutant synapse compared to the control (1.6 per μm vs.
3.4 per μm, respectively) while their overall density did not differ
between control and SMAΔ7 mutant samples (each with 2.4 per μm).
Lastly, likewise in agreementwith results fromﬂuorescencemicroscopy,
SC-coverage of themutant nerve terminal appears incomplete (Fig. 9C′;
double arrowhead).
Discussion
Despite knowledge of the genetic basis of SMA and generation of
mouse models, the cell type(s) and the cellular process(es) responsible
for its pathology remain elusive. This is an important issue in designing
potential therapeutic interventions. One key question is if andwhy SMA
is a disease speciﬁcally of motor neurons, given the ubiquitous
requirement for SMN protein (Cifuentes-Diaz et al., 2001; Frugier et
al., 2000; Schrank et al., 1997; Vitte et al., 2004). The emphasis onmotor
neurons comes from the profound muscle weakness in human patients
and theevidence ofmotorneuron loss frompostmortemexamination of
both humans (Crawford and Pardo, 1996) and of SMA mouse models
(Hsieh-Li et al., 2000; Jablonka et al., 2000; Le et al., 2005). Attempts at
tissue-speciﬁc alteration in SMN expression have suggested motor
neuron involvement (Azzouz et al., 2004; Foust et al., 2010; Gavrilina et
al., 2008; Park et al., 2010b), but failed to demonstrate that SMA results
fromSMNreductiononly inmotorneurons.Moreover, reports of defects
in other cell/tissue types in SMA models (Heier et al., 2010; Liu et al.,
2011; Shababi et al., 2010; Wishart et al., 2010) illustrate that SMA is a
complex disease; it cannot be explained by a simple deterioration of
neuromuscular connections. Even if motor neuron expression is key,
studies have now shown alterations in the synaptic inputs to the motor
neurons themselves play a signiﬁcant role in SMApathogenesis (Ling et
al., 2010; Mentis et al., 2011; Park et al., 2010b).
A key ﬁnding of our study of SMNΔ7 mice is a profound delay in
postnatal neuromuscular development in a set of muscles without
evidence of motor neuron loss or overt failure of neuromuscular
transmission. The loss of force generated by these mutant muscles is
explained, not by deﬁciencies in their innervation, but by the small
size of their muscle ﬁbers. The lack of a deﬁciency in neuromusculartransmission is consistent with other observations in SMAΔ7 mutants
(Kong et al., 2009; Ling et al., 2010; Ruiz et al., 2010). It might be
argued that a different set of muscles than the soleus we chose for our
physiological examinations are those most affected by the disease.
Indeed, there is now strong evidence that a set of motor neurons in
the medial motor column do die in this mouse model and death here
is much more prominent than in the lateral motor column (Mentis et
al., 2011). A death of motor neurons to somemuscles is also supported
by other studies (Kariya et al., 2008; Kong et al., 2009; Murray et al.,
2008). However, the muscles we studied are clearly altered by the
disease. They show a similar reduction in ﬁber size and this reduction
is uniform across all the ﬁbers in these muscles. This ﬁnding is
inconsistent with a progressive disease affecting motor neuron after
motor neuron in thesemuscles; such amechanismwould be expected
to produce alterations within individual motor units in the muscles
and we observed no evidence of such alterations. Rather, it appears
that the disease is uniformly altering all the motor neurons to the 3
muscles we studied or alternatively all the ﬁbers in these muscles. A
possible explanation for some of the discrepancies among the
different mouse models in motor neuron death and synaptic failure
may simply be how rapidly and generally the disease state progresses
and how long themice live following onset of symptoms. For example,
neuroﬁlament accumulation is more pronounced in SMAΔ7 mutants
than in genetically identical mice that lack the SMNΔ7 transgene and
that succumb to the disease ~10 days earlier (Murray et al., 2008).
Therefore, if the disease is mild, progression of the disease might
manifest as motor neuron death and synaptic failure (Kariya et al.,
2008; Park et al., 2010b) whereas if the disease progresses rapidly, the
mice might die from other causes before motor neuron death itself.
Findings in our own study suggest that supplementation of the diet of
the SMAΔ7 mice so as to extend their life span results in an
exaggeration of some of the defects but we still found no evidence
for motor neuron death. Lastly, given the well-known trophic
interdependence of motor neurons and their muscle ﬁber targets
and the profound deﬁcits in muscle ﬁber growth and maturation seen
in the SMAΔ7 mice, it would not be surprising if motor neuron death
in the cases where it is observed is a consequence of this
interdependency (Habgood et al., 1984).
A consistent ﬁnding of our study is severe defects in the postnatal
maturation of muscle and neuromuscular synapses. Postsynaptically,
consistent with a pair of recent reports (Biondi et al., 2008; Kong et al.,
2009), the muscle ﬁbers are slowed in their loss of embryonic myosin
and fail to gain the levels of fast myosin that are present in controls,
even though the muscle-speciﬁc distribution of ﬁber types is retained.
The muscle ﬁbers are small because they fail to grow in size. The
postjunctional folds fail to develop/mature and the AChR plaques
remain immature inmorphology and, from the observations of others,
retain the fetal form of the AChR (Kong et al., 2009). Presynaptically,
the motor nerve terminal fails to produce the normal number and
distribution of synaptic vesicles. Many of the ﬁbers retain polyneur-
onal innervation far longer than expected. Others have reported
altered kinetics of endplate current and reduction in quantal content
(Kong et al., 2009; Ling et al., 2010; Ruiz et al., 2010) consistent with
immature NMJs. Additionally, there are fewer tSCs at mutant NMJs
and their coverage of the nerve terminals is less complete. All of these
descriptors are characteristic of younger stages of neuromuscular
development, suggesting SMA slows this development. It is unclear
why so many different aspects of neuromuscular development should
be slowed, but neuromuscular activity is well known to be a critical
factor here. For example, the synaptogenetic protein agrin alone is
sufﬁcient to drive many aspects of neuromuscular differentiation,
including aggregation of AChR and selective gene transcription from
postsynaptic nuclei (Cohen et al., 1997). However, more complete
differentiation requires activity of postsynaptic muscle ﬁber as well:
stimulation of activity in an otherwise denervated muscle can induce
the γ to ε subunit (fetal to adult isoform) switch in AChR receptor
443Y. Lee et al. / Developmental Biology 356 (2011) 432–444composition (Brenner et al., 1987; see also Rimer et al., 1997) and
maintain the metabolic stability of AChR in the postsynaptic
membrane (Andreose et al., 1993). Similarly, neuromuscular activity
profoundly affects the postnatal loss of polyneuronal innervation
(Thompson, 1983a; Thompson et al., 1979), and postjunctional fold
formation is severely stunted following denervation (Marques et al.,
2000) and in animals that lack cholinergic transmission (Misgeld et
al., 2002). A study using cultured myotubes suggests that electrical
activity may also inﬂuence the organization of sarcomeres (Dutton et
al., 1993); this is also shown by in vivo studies (see for example
Bezakova and Lømo, 2001). One factor that could alter the activity of
SMA motor neurons is the decrease in excitatory synaptic inputs the
motor neurons themselves receive (Ling et al., 2010; Mentis et al.,
2011; Park et al., 2010b), resulting in formation of silent or less active
NMJs that are fully competent for faithful cholinergic transmission
(Ruggiu et al., 2009). In this regard it is interesting to note that
increased use of the neuromuscular system in some mouse models of
SMA leads to amelioration of some of the symptoms (Biondi et al.,
2008).
While it is tempting to attribute many of the developmental delays
we see in SMA-afﬂicted mice to altered neuromuscular activity, it is
clear some aspects of the development of the NMJ are activity
independent. For example, aspects of the nerve contact area, including
the partial maturation of receptors from plaque-like to a circular
conﬁguration can occur in the absence of production and release of
ACh (Misgeld et al., 2002) or in cultured muscle ﬁbers in the complete
absence of neurons (Kummer et al., 2004). Similarly, some evidence
suggests that the development of postjunctional folds depends only
on the deposition of agrin (Cohen et al., 1997). There is also genetic
evidence that molecules within muscle ﬁbers or the extracellular
matrix modify this folding (Adams et al., 2000; Noakes et al., 1995).
Additionally, as astrocytes produce molecules that potentiate synap-
togenesis (Christopherson et al., 2005), the overall reduction in
synapse density (Park et al., 2010b) and increased motor neuron–
microglia interactions (Ling et al., 2010) suggest possible glial
involvement in SMA pathogenesis. Our results of deﬁcits in tSC
number and their coverage of NMJs are consistent with this
hypothesis. Together, these observations emphasize the complexity
of the etiology of this disease and suggest it cannot be simply
explained by decreased activity of motor neurons either.
Interestingly, in mouse tissues it appears that SMN expression is
highest during embryonic and early postnatal stages and declines
rapidly thereafter (Gabanella et al., 2005). In addition, the maximum
efﬁcacy of a virus-mediated replacement therapy in SMA mice was
achieved with early postnatal initiation (P2) and declines rapidly
thereafter (Foust et al., 2010). This raises the possibility that
sensitivity to SMN reduction is highest in younger animals and results
in severe forms of SMA, such as that present in the SMAΔ7 mouse
used in this study, and this early reduction leads to developmental
delays (Hausmanowa-Petrusewicz and Vrbova, 2005) such as
reported here. However, a reduction in SMN that occurs later in
development or is less severe might produce an entirely different
disease. This also suggests the time requirements for effective
therapeutic interventions might be quite different among the
different forms of SMA.
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